FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2182009988> ?p ?o ?g. }

• W2182009988 abstract "ABSTRACT Background: Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic cancer. Around 75% of the patients are in advanced clinical stages at diagnosis. Despite improvements in cytoreductive surgery and primary chemotherapy over 80% of advanced stage patients will relapse. Racotumomab-alum is a therapeutic cancer vaccine composed by a murine monoclonal antibody (racotumomab) and alum as adjuvant. It is able to induce a specific antibody response against N-glycolilGM3 tumor associated antigen. Its antitumoral activity has been demonstrated in melanoma, breast cancer and NSCLC. The aim of this clinical trial is to evaluate the efficacy and safety of racotumomab-alum as maintenance treatment for recurrent platinum-sensitive EOC. Trial design: This phase II/III multicenter, controlled clinical trial will include 88 patients with histologically confirmed EOC, clinical stage II-IV, with two prior platinum-based chemotherapy treatments and objective response after last regimen, with ECOG performance status 0-2, that signed informed consent, with normal renal, haematologic and hepatic functions. Will be excluded patients with prior treatment with racotumomab-alum or any investigational drug, platinum-resistant disease, pregnancy or breast feeding, history of brain metastasis or spinal cord compression, uncontrolled chronic diseases, previous adverse reactions to vaccines, history of immunodeficiency or autoimmune disease. Patients will be randomized with 1:1 ratio to receive racotumomab-alum or best supportive care. The primary endpoint will be progression free survival (PFS) and we will also evaluate OS, Safety, and Immunological response. The NGcGM3 expression in tumor samples and immunophenotype of tumor infiltrating cells will be evaluated to correlate with clinical endpoints. Racotumomab-alum treatment consist in 5 biweekly intradermal doses (induction phase) followed by monthly re-immunization (maintenance phase) until unacceptable toxicity or PS worsening. Treatment will not be stopped at progressive disease; other chemotherapy lines will be given concomitantly. We have hypothesized a 4 months advantage in PFS for vaccinated group. Disclosure: All authors have declared no conflicts of interest." @default.
• W2182009988 created "2016-06-24" @default.
• W2182009988 creator A5003434643 @default.
• W2182009988 creator A5004238868 @default.
• W2182009988 creator A5007460209 @default.
• W2182009988 creator A5011619590 @default.
• W2182009988 creator A5042963282 @default.
• W2182009988 creator A5047030045 @default.
• W2182009988 creator A5049969436 @default.
• W2182009988 creator A5050169091 @default.
• W2182009988 creator A5063941146 @default.
• W2182009988 creator A5072756465 @default.
• W2182009988 creator A5073195438 @default.
• W2182009988 creator A5074443410 @default.
• W2182009988 creator A5078576724 @default.
• W2182009988 creator A5090945751 @default.
• W2182009988 creator A5091692308 @default.
• W2182009988 date "2014-09-01" @default.
• W2182009988 modified "2023-09-27" @default.
• W2182009988 title "Racotumomab-Alum Vaccine for Maintenance Treatment of Recurrent Platinum-Sensitive Epithelial Ovarian Cancer Patients" @default.
• W2182009988 doi "https://doi.org/10.1093/annonc/mdu342.32" @default.
• W2182009988 hasPublicationYear "2014" @default.
• W2182009988 type Work @default.
• W2182009988 sameAs 2182009988 @default.
• W2182009988 citedByCount "0" @default.
• W2182009988 crossrefType "journal-article" @default.
• W2182009988 hasAuthorship W2182009988A5003434643 @default.
• W2182009988 hasAuthorship W2182009988A5004238868 @default.
• W2182009988 hasAuthorship W2182009988A5007460209 @default.
• W2182009988 hasAuthorship W2182009988A5011619590 @default.
• W2182009988 hasAuthorship W2182009988A5042963282 @default.
• W2182009988 hasAuthorship W2182009988A5047030045 @default.
• W2182009988 hasAuthorship W2182009988A5049969436 @default.
• W2182009988 hasAuthorship W2182009988A5050169091 @default.
• W2182009988 hasAuthorship W2182009988A5063941146 @default.
• W2182009988 hasAuthorship W2182009988A5072756465 @default.
• W2182009988 hasAuthorship W2182009988A5073195438 @default.
• W2182009988 hasAuthorship W2182009988A5074443410 @default.
• W2182009988 hasAuthorship W2182009988A5078576724 @default.
• W2182009988 hasAuthorship W2182009988A5090945751 @default.
• W2182009988 hasAuthorship W2182009988A5091692308 @default.
• W2182009988 hasBestOaLocation W21820099881 @default.
• W2182009988 hasConcept C121608353 @default.
• W2182009988 hasConcept C126322002 @default.
• W2182009988 hasConcept C143998085 @default.
• W2182009988 hasConcept C2776694085 @default.
• W2182009988 hasConcept C2779013556 @default.
• W2182009988 hasConcept C2780427987 @default.
• W2182009988 hasConcept C2781413609 @default.
• W2182009988 hasConcept C535046627 @default.
• W2182009988 hasConcept C71924100 @default.
• W2182009988 hasConceptScore W2182009988C121608353 @default.
• W2182009988 hasConceptScore W2182009988C126322002 @default.
• W2182009988 hasConceptScore W2182009988C143998085 @default.
• W2182009988 hasConceptScore W2182009988C2776694085 @default.
• W2182009988 hasConceptScore W2182009988C2779013556 @default.
• W2182009988 hasConceptScore W2182009988C2780427987 @default.
• W2182009988 hasConceptScore W2182009988C2781413609 @default.
• W2182009988 hasConceptScore W2182009988C535046627 @default.
• W2182009988 hasConceptScore W2182009988C71924100 @default.
• W2182009988 hasLocation W21820099881 @default.
• W2182009988 hasOpenAccess W2182009988 @default.
• W2182009988 hasPrimaryLocation W21820099881 @default.
• W2182009988 isParatext "false" @default.
• W2182009988 isRetracted "false" @default.
• W2182009988 magId "2182009988" @default.
• W2182009988 workType "article" @default.